Neuraxis, Inc. (NRXS)
NYSE: NRXS · Electromedical & Electrotherapeutic Apparatus · Carmel, IN · filing with the SEC since 2022
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 19, 2026 | Mar 20, 2025 | Apr 16, 2024 | · |
| Revenue | 3,569,282 | 2,685,925 | 2,460,049 | 2,684,735 |
| Cost of revenue | 562,916 | 362,002 | 303,345 | 297,060 |
| Gross profit | 3,006,366 | 2,323,923 | 2,156,704 | 2,387,675 |
| Research and development | 493,611 | 433,614r | 169,315 | 225,610 |
| General and administrative | 8,062,689 | 7,578,242r | 8,328,315 | 5,123,420 |
| Operating income | -7,829,908 | -7,156,817 | -6,664,495 | -3,372,238 |
| Interest expense | 73,969 | 174,328 | 476,416 | 318,666 |
| Other income (expense), net | 29,353 | -1,084,684 | -7,962,188 | -1,407,823 |
| Net income | -7,800,555 | -8,241,501 | -14,626,683 | -4,780,061 |
| Net income to common shareholders | -8,615,152 | -8,452,769 | -14,626,683 | -5,544,954 |
| Earnings per share, basic | -0.95 | -1.22 | -4.50 | -2.77 |
| Earnings per share, diluted | -0.95 | -1.22 | -4.50 | -2.77 |
| Weighted average shares, basic | 9,083,399 | 6,918,887 | 3,252,328 | 2,003,322 |
| Weighted average shares, diluted | 9,083,399 | 6,918,887 | 3,252,328 | 2,003,322 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding